Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Underutilisation of cardiovascular medications among at-risk individuals.

Lewis SJ, Robinson JG, Fox KM, Grandy S; SHIELD Study Group.

Int J Clin Pract. 2010 Apr;64(5):604-10. doi: 10.1111/j.1742-1241.2009.02258.x. Epub 2009 Nov 11.

2.

Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services study.

Zachariadou T, Stoffers HE, Christophi CA, Philalithis A, Lionis C.

BMC Health Serv Res. 2008 Jul 16;8:148. doi: 10.1186/1472-6963-8-148.

3.

Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).

Mehta S, Wells S, Riddell T, Kerr A, Pylypchuk R, Marshall R, Ameratunga S, Chan WC, Thornley S, Crengle S, Harrison J, Drury P, Elley CR, Bell F, Jackson R.

J Prim Health Care. 2011 Jun 1;3(2):93-101.

PMID:
21625656
4.

The young at risk of CVD are the least likely to receive preventive cardiovascular medications in New Zealand.

Hobbs FD.

J Prim Health Care. 2011 Jun 1;3(2):92. No abstract available.

PMID:
21625655
5.

Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients.

Lim MY, Pruthi RK.

Blood Coagul Fibrinolysis. 2011 Jul;22(5):402-6. doi: 10.1097/MBC.0b013e328345f582.

PMID:
21451396
6.

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Reiner Z, Keil U; EUROASPIRE Study Group.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):530-40. doi: 10.1097/HJR.0b013e3283383f30.

PMID:
20577089
7.

Best medical intervention for arterial disease or wishful thinking.

Abbott A.

Eur J Vasc Endovasc Surg. 2011 Apr;41(4):509-10. doi: 10.1016/j.ejvs.2011.01.008. Epub 2011 Feb 1. No abstract available.

8.

Comments regarding 'Best medical therapy or wishful thinking in carotid disease? a single centre audit in Germany'.

Milner R.

Eur J Vasc Endovasc Surg. 2011 Apr;41(4):507-8. doi: 10.1016/j.ejvs.2010.12.019. Epub 2011 Jan 21. No abstract available.

9.

Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe.

Morrell J, Zeymer U, Baumgartner I, Limbourg T, Röther J, Bhatt DL, Steg PG; REACH Registry Investigators.

Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):270-7. doi: 10.1097/HJR.0b013e32833cca34.

PMID:
20606595
10.

Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy?

Bupha-Intr O, Rose SB, Lawton BA, Elley CR, Dowell AC.

N Z Med J. 2010 Feb 19;123(1309):26-36.

PMID:
20186240
11.

Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA.

Ovbiagele B, Hills NK, Saver JL, Johnston SC.

Neurology. 2006 Feb 14;66(3):313-8.

PMID:
16476928
12.

Preferential adherence to immunosuppressive over nonimmunosuppressive medications in kidney transplant recipients.

Terebelo S, Markell M.

Transplant Proc. 2010 Nov;42(9):3578-85. doi: 10.1016/j.transproceed.2010.08.027.

PMID:
21094819
13.

Best medical therapy or wishful thinking in carotid disease? A single-centre audit in Germany.

Lutz HJ, Sacuiu RD, Gahl B, Savolainen H.

Eur J Vasc Endovasc Surg. 2011 Apr;41(4):501-6. doi: 10.1016/j.ejvs.2010.12.006. Epub 2011 Feb 3.

14.

Most people don't take heart drugs as directed.

[No authors listed]

Harv Mens Health Watch. 2012 Nov;17(4):1, 8. No abstract available.

PMID:
23330206
15.

The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.

Chapman RH, Ferrufino CP, Kowal SL, Classi P, Roberts CS.

Int J Clin Pract. 2010 Jan;64(2):169-81. doi: 10.1111/j.1742-1241.2009.02196.x. Review.

PMID:
20089007
16.

The next 10 years in personalized medicine in cardiology.

Tantry US, Gurbel PA.

Expert Rev Cardiovasc Ther. 2013 Aug;11(8):933-5. doi: 10.1586/14779072.2013.814823. No abstract available.

PMID:
23984921
17.
18.

Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice.

Semb AG, Rollefstad S, van Riel P, Kitas GD, Matteson EL, Gabriel SE.

Ann Rheum Dis. 2014 Jul;73(7):1284-8. doi: 10.1136/annrheumdis-2013-204792. Epub 2014 Mar 7.

PMID:
24608403
19.

[Influence of cardiovascular risk factors on prescribing of antihypertensives].

Vaur L, Amar J, Perret M, Bailleau C, Etienne S, Chamontin B.

Arch Mal Coeur Vaiss. 2001 Aug;94(8):846-50. French.

PMID:
11575216
20.

Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women?

Roberts BH, Thompson PD.

Gend Med. 2006 Mar;3(1):5-12. Review. No abstract available.

PMID:
16638596

Supplemental Content

Support Center